GlassScriptPhysician profile
Syed T Rab
NPI 1891751301
$10,359.54
in general payments reported to CMS, 2019-2025
40 companies · $1,570 in 2025
The $1,570 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,160 · 2020: $827 · 2021: $1,544 · 2022: $1,524 · 2023: $1,808 · 2024: $1,927 · 2025: $1,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,246 · Education: $58.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,245.59 |
| Education | $58.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,158.29 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $1,027.09 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Opko Pharmaceuticals, LLC | $882.12 | 2019-2025 | Rayaldee |
| Akebia Therapeutics INC | $831.83 | 2019-2025 | Auryxia, Vafseo |
| Calliditas Therapeutics US INC. | $674.63 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $632.16 | 2019-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $601.36 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $543.81 | 2019-2025 | Velphoro, Velphoro |
| Glaxosmithkline, LLC. | $540.10 | 2020-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $478.00 | 2019-2024 | Lokelma, Farxiga |
| Aurinia Pharma U.S., INC. | $474.12 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $351.53 | 2023 | Krystexxa |
| Daiichi Sankyo INC. | $334.96 | 2019-2023 | Injectafer |
| Mallinckrodt Hospital Products INC. | $256.34 | 2020-2024 | Acthar |
| Shield Therapeutics INC | $184.33 | 2023-2025 | Accrufer |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Rab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.